Essential Premium

From Deep Losses to Remarkable Gains: Biopharma’s Wildest Year in Recent Memory

A spring pivot in sentiment turned one of the sector’s toughest stretches into a breakout year for the specialist funds.

The Numbers Are in on Short Sellers’ Losing Year

Nvidia was the shorts’ biggest loser, but they profited on companies like Apollo and UnitedHealth.

Sponsored

Venezuela and Oil Prices

Valiant Topped the Tiger Crowd in 2025

Most Tiger Cubs and Grandcubs posted strong results in either their long-short or long-only funds.

Related Content

Life Sciences Hedge Fund Perceptive Preps a New SPAC

Stephen Taub

How Blackstone Bolted Past Rivals in Life Sciences

Jonathan Kandell

Why CalSTRS and Family Offices Love This Life Sciences VC Firm

Michael Thrasher

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram